Arcellx Inc(ACLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.05 | Insider Own | 22.44% | Shs Outstand | 57.9M | Perf Week | - |
| Market Cap | 6.73B | Forward P/E | - | EPS next Y | 60.75% | Insider Trans | -1.1% | Shs Float | 45.4M | Perf Month | 0.24% |
| Enterprise Value | 6.33B | PEG | - | EPS next Q | -1.07 | Inst Own | 72.93% | Short Float | 3.97% | Perf Quarter | 71.9% |
| Income | -0.23B | P/S | 302.05 | EPS this Y | 14.7% | Inst Trans | - | Short Ratio | 0.75 | Perf Half Y | 30.49% |
| Sales | 0.02B | P/B | 16.57 | EPS next 5Y | - | ROA | -34.81% | Short Interest | 1.80M | Perf YTD | 76.49% |
| Book/sh | 6.95 | P/C | 14.95 | EPS past 3/5Y | 1.68% -33.56% | ROE | -53.42% | 52W High | -0.05% ($115.13) | Perf Year | 80.62% |
| Cash/sh | 7.7 | P/FCF | - | Sales past 3/5Y | - | ROIC | -51.25% | 52W Low | 140.43% ($47.86) | Perf 3Y | 178.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -103.5% | Gross Margin | 70.03% | Volatility(W/M) | 0.09% 0.12% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 284.18 | Sales Y/Y TTM | -79.35% | Oper. Margin | -1135.61% | ATR (14) | 0.4 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.44 | EPS Q/Q | -15.71% | Profit Margin | -1027.25% | RSI (14) | 79.85 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.44 | Sales Q/Q | -89.17% | SMA20 | 0.14% ($114.91) | Beta | 0.18 | Target Price | $115 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/02/26 | SMA50 | 4.72% ($109.88) | Rel Volume | 0 | Prev Close | $115.07 |
| Employees | 209 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 0.92% -21.75% | SMA200 | 37.83% ($83.49) | Avg Volume(3M) | 2.40M | Price | $115.07 |
| IPO | 2022/2/4 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
A clinical-stage biotech developing next-generation CAR-T cell therapies for the treatment of multiple myeloma. Its lead pipeline candidate is anito-cel, a BCMA-targeting CAR-T therapy, and the company has entered into a global commercialization partnership with Gilead Sciences.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
ACLX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.7% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $30,205. Peers typically go for $1,711.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +178.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 72.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #39 of 598 in the industry
Based on market cap of $7B.
FAQ
What kind of company is ACLX?
ACLX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACLX?
The market cap of ACLX is approximately $6.7B, ranking 1,165 within its sector.
What is the 52-week high and low for ACLX?
ACLX has recorded a 52-week high of $115.13 and a low of $47.86.
